je.st
news
Home
› FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate
FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate
2016-06-01 05:41:19| drugdiscoveryonline Home Page
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, recently announced that the U.S. Food and Drug Administration (FDA) has designated the company’s novel antifungal product candidate, CD101 topical, as a Qualified Infectious Disease Product (QIDP), with Fast Track status for its development program
Tags: product
fast
track
candidate
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||